Conjupro Biotherapeutics, Inc.
Clinical trials sponsored by Conjupro Biotherapeutics, Inc., explained in plain language.
-
Experimental cancer drug CPO-100 trial halted early
Disease control TerminatedThis early-phase study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New drug CPO107 tested in lymphoma patients – early trial stopped
Disease control TerminatedThis early study tested a new drug, CPO107, in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Conjupro Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC